This bill requires New York state agencies receiving opioid settlement funds to submit annual public reports detailing how these funds are spent. The reports must include baseline funding data, specific recipient information (including program details and populations served), the criteria for awarding funds, and evidence-based analysis of program effectiveness in reducing substance use disorders. It also prohibits government entities from pursuing legal claims against companies released under the statewide opioid settlement agreement after June 2021. All reports must be published as a public dashboard on government websites by November 1st each year.
Includes all FDA approved forms and doses of Naloxone as opioid antagonists in the state definition of opioid antagonists; requires the department of health to approve all forms and doses of Naloxone approved by the FDA as opioid antagonists.
This bill establishes the "Sickle Cell Treatment Act" to improve care for sickle cell disease patients in New York. It designates five "centers for excellence" (with two north of Putnam/Orange counties) and ten outpatient treatment centers based on patient populations, providing each center with annual funding ($500,000 for excellence centers, $250,000 for outpatient centers) to support specialized care, research, and equipment. The bill also modifies opioid prescribing rules to exempt sickle cell disease patients from a three-month opioid limit, ensuring they can receive necessary pain management without restrictive barriers. These changes directly affect hospitals designated as centers, sickle cell patients requiring specialized care, and healthcare providers managing chronic pain.
Bill S 3474 enhances New York's Assisted Outpatient Treatment (AOT) program, commonly known as Kendra's Law, by strengthening oversight and eliminating its scheduled expiration to ensure the program continues without interruption. The bill adds specific requirements for program coordinators to monitor treatment compliance, coordinate services with community providers, and review clinical needs before court orders expire, while mandating community service directors to conduct timely investigations and document processes. It also requires the state to create an educational pamphlet explaining the AOT petition process in plain language for the public. This bill directly affects individuals under court-ordered AOT, mental health program staff, and the public seeking information about the program.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
This bill (S 5490) allows individuals in drug or alcohol recovery to request a special "R" indicator on their driver's license when renewing or applying for a new license. The "R" mark would alert medical professionals during emergencies that the driver is in recovery, without requiring additional fees beyond standard license costs. It directly affects people in recovery who choose to opt-in, providing a clear identifier for healthcare providers in medical situations. The bill makes this option available through standard license application processes with no new requirements for state agencies.
This bill requires all New York high schools to keep opioid overdose-reversal medication (like naloxone) on hand and designate at least one trained staff member to administer it during all school hours and after-school activities. Schools must ensure the medication is accessible and that at least one employee has completed a state-approved training course on its use. The law applies directly to high schools and their designated staff, mandating immediate availability of the medication for emergencies. It does not change existing health protocols but adds a specific requirement for opioid overdose response in school settings.
This bill amends New York's financial services law to explicitly include ambulance services to an emergency room as part of "emergency services" for surprise billing protections. It requires health insurance plans to cover non-participating ambulance providers' emergency services (including ambulance rides to the ER) without charging patients more out-of-pocket than they would with a participating provider. The law prohibits ambulance providers from billing patients for costs beyond standard copays, coinsurance, or deductibles. It also extends these protections to mobile crisis intervention services provided by licensed mental health or addiction services providers.
This bill requires all New York colleges with on-campus housing to provide and maintain opioid antagonists (medications like naloxone) for emergency use. It mandates that resident assistants receive training on administering these medications and that supplies be accessible in all college-owned housing buildings. The policy directly affects colleges, resident assistants, and students/staff who may experience an opioid overdose on campus. It specifies that colleges must stock sufficient quantities approved by the health commissioner, ensuring immediate access during emergencies without requiring prior history of opioid use.
Requires health insurers to provide coverage for non-opioid treatments utilized for pain management including, but not limited to a drug or biological product that is indicated to produce analgesia without acting upon the body's opioid receptors that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed; or an implantable, reusable, or disposable medical device for the intended use of managing or treating pain that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed.
